Jane Street
GALT icon

Jane Street’s Galectin Therapeutics GALT Stock Holding History

Jane Street’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.8K Sell
18,700
-148,700
-89% -$385K ﹤0.01% 10671
2026
Q1 		$467K Sell
167,400
-12,900
-7% -$39.2K ﹤0.01% 8221
2025
Q4 		$750K Buy
+180,300
New +$949K ﹤0.01% 6782
2025
Q1 		– Sell
-89,500
Closed -$115K – 9808
2024
Q4 		$115K Buy
+89,500
New +$214K ﹤0.01% 8708
2022
Q1 		– Sell
-42,100
Closed -$87K – 10535
2021
Q4 		$87K Sell
42,100
-5,000
-11% -$14.3K ﹤0.01% 9309
2021
Q3 		$183K Buy
47,100
+34,500
+274% +$117K ﹤0.01% 8920
2021
Q2 		$40K Buy
+12,600
New +$44.8K ﹤0.01% 9545

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's GALT Position: Q2 2026 in Review

Jane Street sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 194,868 shares — an estimated $505K sold.

Jane Street first reported a position in GALT in Q3 2013 and held it in 15 quarters. The position peaked at $1.58M in Q2 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Jane Street reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 194,868 Galectin Therapeutics shares in Q2 2026, an estimated $505K.
  • Jane Street first reported a position in Galectin Therapeutics in Q3 2013 and held it in 15 quarters.
  • Jane Street's Galectin Therapeutics position peaked at $1.58M in Q2 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.